Alexander Drilon

Alexander Drilon

UNVERIFIED PROFILE

Are you Alexander Drilon?   Register this Author

Register author
Alexander Drilon

Alexander Drilon

Publications by authors named "Alexander Drilon"

Are you Alexander Drilon?   Register this Author

83Publications

3281Reads

38Profile Views

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.

J Thorac Oncol 2019 Sep 20;14(9):1666-1671. Epub 2019 Jun 20.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.06.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708730PMC
September 2019

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Lung Cancer 2019 Sep 23;137:113-122. Epub 2019 Sep 23.

Hospital Sírio-Libanes, Oncology Center, Sao Paulo, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.09.017DOI Listing
September 2019

The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement.

Hum Pathol 2019 Jun 1;88:66-77. Epub 2019 Apr 1.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2019.03.004DOI Listing
June 2019

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with -Mutant Lung Cancers.

Clin Cancer Res 2019 Feb 25;25(3):1063-1069. Epub 2018 Jul 25.

Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347551PMC
February 2019

NTRK fusion-positive cancers and TRK inhibitor therapy.

Nat Rev Clin Oncol 2018 12;15(12):731-747

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0113-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419506PMC
December 2018

CT features of HER2-mutant lung adenocarcinomas.

Clin Imaging 2018 Sep - Oct;51:279-283. Epub 2018 Jun 7.

Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinimag.2018.05.028DOI Listing
November 2018

Learning All That We Can From MyPathway.

J Clin Oncol 2018 08 1;36(23):2450-2451. Epub 2018 Jun 1.

Jessica J. Tao, Alison M. Schram, Memorial Sloan Kettering Cancer Center, New York, NY; and James J. Harding, Alexander Drilon, and David M. Hyman, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.4728DOI Listing
August 2018

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

J Clin Oncol 2018 08 10;36(24):2532-2537. Epub 2018 Jul 10.

Bob T. Li, Ronglai Shen, Darren Buonocore, Zachary T. Olah, Ai Ni, Michelle S. Ginsberg, Gary A. Ulaner, Michael Offin, Daniel Feldman, Helen H. Won, Edyta B. Brzostowski, Gregory J. Riely, David B. Solit, David M. Hyman, Alexander Drilon, Charles M. Rudin, Michael F. Berger, Jose Baselga, Maurizio Scaltriti, Maria E. Arcila, and Mark G. Kris, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY; Bob T. Li, Nick Pavlakis, and Stephen Clarke, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; and Todd Hembrough, Fabiola Cecchi, and Sarit Schwartz, NantOmics, Rockville, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.77.9777
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.77.9777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366814PMC
August 2018

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of , , and fusion-positive solid tumors.

Ther Clin Risk Manag 2018 20;14:1247-1252. Epub 2018 Jul 20.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/TCRM.S147381DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055893PMC
July 2018

Tumor-Agnostic Drug Development.

Am Soc Clin Oncol Educ Book 2018 May;38:184-187

From the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200831DOI Listing
May 2018

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Nat Rev Clin Oncol 2018 03 14;15(3):151-167. Epub 2017 Nov 14.

National Cancer Center, 11 Hospital Drive, Singapore 169610, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.175DOI Listing
March 2018

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

N Engl J Med 2018 02;378(8):731-739

From Memorial Sloan Kettering Cancer Center (A. Drilon, J.F.H., R.B., M.L., D.M.H.) and Weill Cornell Medical College (A. Drilon, D.M.H.), New York; University of Texas Southwestern Medical Center-Children's Health, Dallas (T.W.L.); Stanford Cancer Center, Stanford University, Palo Alto (S.K.), Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California (L.M.), and UCLA David Geffen School of Medicine (N.F.), Los Angeles, and Loxo Oncology, South San Francisco (B.B.T., K.E., S.C., N.C.K., M.C.C.) - all in California; Dana-Farber-Boston Children's Cancer and Blood Disorders Center (S.G.D.), Dana-Farber Cancer Institute (G.D.D., M.N.), Ludwig Center at Harvard (G.D.D.), and Massachusetts General Hospital (A.F.F.) - all in Boston; the Finsen Center, Rigshospitalet, Copenhagen (U.N.L.); University of Colorado, Aurora (R.C.D.); St. Jude Children's Research Hospital, Memphis (A.S.P.), and Vanderbilt University, Nashville (J.B.) - both in Tennessee; Cincinnati Children's Hospital Medical Center, Cincinnati (B.T.); University Hospitals of Cleveland Medical Center (A. Dowlati) and Taussig Cancer Institute, Cleveland Clinic (D.P.S.S.), Cleveland; University of Pennsylvania Perelman School of Medicine, Department of Otorhinolaryngology and Head and Neck Surgery, and the Abramson Cancer Center (M.S.B.), and Fox Chase Cancer Center (W.S.E.-D.), Philadelphia; University of Washington-Seattle Cancer Care Alliance (C.B.), Seattle Children's Hospital (E.R.R.), and Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center (D.S. Hawkins), Seattle; University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B., D.S. Hong); Inova Schar Cancer Institute, Falls Church, VA (J.D.); START Madrid, Centro Integral Oncológico Clara Campal, Madrid (V.B.); Nemours Children's Hospital, Orlando (R.N.), and Memorial Cancer Institute-Florida International University, Miami (L.E.R.) - both in Florida; Oregon Health and Science University, Portland (M.T.); and WVU Cancer Institute, West Virginia University, Morgantown (P.C.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1714448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857389PMC
February 2018

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.

Nat Rev Clin Oncol 2017 Dec 31;14(12):735-748. Epub 2017 Aug 31.

Department of Medicine 1275 York Avenue, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.127DOI Listing
December 2017

Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.

Nat Commun 2017 07 11;8:15987. Epub 2017 Jul 11.

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms15987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508201PMC
July 2017

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Transl Lung Cancer Res 2017 Jun;6(3):393-395

Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2017.04.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504114PMC
June 2017

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

J Clin Oncol 2017 May 13;35(13):1403-1410. Epub 2017 Mar 13.

Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.9352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559893PMC
May 2017

Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy.

Curr Oncol Rep 2017 Apr;19(4):24

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 300 East 66th Street, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-017-0587-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428198PMC
April 2017

The activity, safety, and evolving role of brigatinib in patients with -rearranged non-small cell lung cancers.

Onco Targets Ther 2017 6;10:1983-1992. Epub 2017 Apr 6.

Developmetal Therapeutics, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S109295DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388194PMC
April 2017

Targeting RET-rearranged lung cancers with multikinase inhibitors.

Oncoscience 2017 Mar 14;4(3-4):23-24. Epub 2017 Apr 14.

Developmetal Therapeutics, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncoscience.345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441470PMC
March 2017

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

J Thorac Oncol 2017 01 26;12(1):15-26. Epub 2016 Oct 26.

University of Colorado Cancer Center, Aurora, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.10.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603268PMC
January 2017

Targeted therapy outcomes in RET-rearranged lung cancers: drug or driver?

Authors:
Alexander Drilon

Lancet Respir Med 2017 01 4;5(1):5-6. Epub 2016 Nov 4.

Thoracic Oncology Service and Developmental Therapeutics Clinic, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(16)30369-1DOI Listing
January 2017

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

Lung Cancer 2016 12 17;102:21-27. Epub 2016 Oct 17.

Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.10.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441998PMC
December 2016

MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.

Authors:
Alexander Drilon

Clin Cancer Res 2016 06 23;22(12):2832-4. Epub 2016 Mar 23.

Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0229DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911276PMC
June 2016

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.

Adv Exp Med Biol 2016 ;893:155-178

Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-24223-1_8DOI Listing
May 2016

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.

Clin Cancer Res 2016 Feb 31;22(3):553-9. Epub 2015 Aug 31.

Weill Cornell Medical College, New York, New York. Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0339DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819316PMC
February 2016

Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.

J Thorac Oncol 2015 Dec;10(12):1713-9

*Thoracic Oncology Service, Department of Medicine, †Department of Epidemiology and Biostatistics, ‡Department of Radiology, and §Department of Pathology, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153509
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000671DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760768PMC
December 2015

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

J Thorac Oncol 2015 Dec;10(12):1670-4

*Department of Medicine, Massachusetts General Hospital, Boston, MA; †Department of Pathology, Massachusetts General Hospital, Boston, MA; ‡Memorial Sloan Kettering Cancer Center, New York, NY; ‖Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; §Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; ¶Department of Medicine, Georgetown University Medical Center, Washington, DC; #University of California Irving Health, Orange, CA; **Dana-Farber Cancer Institute, Boston, MA; ††Beth Israel Deaconess Medical Center, Boston, MA; and ‡‡Ignyta, Inc., San Diego, CA.

View Article

Download full-text PDF

Source
http://ignyta.com/wp-content/uploads/2016/01/Durable-Clinica
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S155608641535087
Publisher Site
http://dx.doi.org/10.1097/01.JTO.0000473485.38553.f0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643748PMC
December 2015

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

JAMA Oncol 2015 Oct;1(7):982-4

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York4Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.1066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665629PMC
October 2015

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

Proc Natl Acad Sci U S A 2015 Sep 8;112(39):E5381-90. Epub 2015 Sep 8.

Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239; Howard Hughes Medical Institute, Portland, OR 97239;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1515281112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593101PMC
September 2015

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

Cancer Discov 2015 Aug 13;5(8):842-9. Epub 2015 May 13.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-1467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658654PMC
August 2015

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.

Clin Cancer Res 2015 Apr 28;21(8):1935-43. Epub 2014 Oct 28.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401580PMC
April 2015

A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.

J Thorac Oncol 2014 Sep;9(9):1272-7

*Memorial Sloan Kettering Cancer Center, New York, NY; †Tokyo Medical and Dental University, Tokyo, Japan; and ‡Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133740PMC
September 2014

Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles.

J Thorac Oncol 2014 Jan;9(1):e1-3

*Department of Pathology, †Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; ‡Computational Biology Program, Sloan-Kettering Institute, New York, New York; and §Department of Medicine Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a471c3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868006PMC
January 2014

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Cancer Discov 2013 Jun 26;3(6):630-5. Epub 2013 Mar 26.

Departments of Medicine Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160032PMC
June 2013

Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.

Lancet Oncol 2012 Oct;13(10):e418-26

Department of Medicine Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470204512
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S147020451270291
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(12)70291-7DOI Listing
October 2012

Acute promyelocytic leukemia in HIV-infected adults: a case report and review of therapeutic considerations.

Clin Lymphoma Myeloma Leuk 2010 Oct;10(5):E47-52

Department of Medicine, St. Luke's Roosevelt Hospital Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLML.2010.n.075DOI Listing
October 2010

Systemic approaches for multifocal bronchioloalveolar carcinoma: is there an appropriate target?

Oncology (Williston Park) 2010 Sep;24(10):888-98, 900

Albert Einstein College of Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
September 2010